Editas Medicine Inc
editasmedicine.comWhat Do They Do?
Develops CRISPR gene-editing medicines for people with serious diseases and licenses its gene-editing technology to pharmaceutical and biotechnology partners.
10-K for FY2025, filed Mar 9, 2026We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of…View ↗
We are also leveraging our gene editing technology to drive the development of CRISPR-based medicines in therapeutic areas outside of our…View ↗
In addition, we are leveraging our intellectual property portfolio to drive potential out-licensing opportunities that can provide…View ↗
How Do They Make Money?
Partners pay for licenses and research work through upfront fees and research-cost reimbursements; they may also pay when development or regulatory milestones are reached and owe royalties on licensed-product sales.
10-K for FY2025, filed Mar 9, 2026The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company enters into…View ↗
The Company’s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method…View ↗
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to…View ↗
$40.5M
-
10-K for FY2025, filed Mar 9, 2026
$40.5M ↗
Who Are Their Customers?
Pharmaceutical and biotechnology companies work directly with Editas through research collaborations and licenses to its gene-editing technology.
10-K for FY2025, filed Mar 9, 2026
Do Revenues Turn Into Profits?
No. It lost $160.1M in FY2025.
10-K for FY2025, filed Mar 9, 2026
−$160MView ↗
10-K for FY2025, filed Mar 9, 2026
−$160.1MView ↗
10-K for FY2025, filed Mar 9, 2026
−$165.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$18.2MView ↗
- ▼ −66% (Loss)
- vs −$53.2M in Q2 FY2025
-
Apr 7, 2026
Replaced Ernst & Young with PwC as independent auditor
The audit committee appointed PwC after soliciting proposals and conducting a formal review.
Sources
8-K, filed Apr 7, 2026
On April 1, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Editas Medicine, Inc. (the “Company”) (i)…View ↗
Growing. Revenue grew 59% in 4 years, from $25.5M in FY2021 to $40.5M in FY2025, about 12% a year.
From ex vivo treatments to in vivo editing
The older report centered on ex vivo gene-edited treatments for blood disorders, while the latest centers on in vivo editing for elevated cholesterol and other tissues.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Mar 9, 2026We seek to be a leader in in vivo gene editing, leveraging cutting edge gene editing technology to deliver transformative therapies that…View ↗
In September 2025, we announced the nomination of our lead in vivo development candidate, EDIT-401, an experimental, potential…View ↗
Our in vivo discovery and development efforts further include other cells and tissues, with the goal of selecting therapeutic targets we…View ↗
Who Do They Compete With?
Competes with AccurEdit Therapeutics, CRISPR Therapeutics, Eli Lilly, EmendoBio, nChroma Bio, Scribe Therapeutics, Tune Therapeutics, Yoltech Therapeutics, Beam Therapeutics, BRL Medicine, Ensoma, Genetix Biotherapeutics, Vertex, Caribou Biosciences, Intellia Therapeutics, Mammoth Biosciences, Prime Medicine, Sangamo Therapeutics, Amgen, and Regeneron Pharmaceuticals
10-K for FY2025, filed Mar 9, 2026We compete in the segments of the pharmaceutical, biotechnology, and other related markets that utilize technologies encompassing genomic…View ↗
Loading...
